Ascendis Pharma Statistics
Total Valuation
Ascendis Pharma has a market cap or net worth of $16.84 billion. The enterprise value is $17.21 billion.
| Market Cap | 16.84B |
| Enterprise Value | 17.21B |
Important Dates
The next confirmed earnings date is Thursday, August 13, 2026, before market open.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Ascendis Pharma has 65.92 million shares outstanding. The number of shares has increased by 5.21% in one year.
| Current Share Class | 65.92M |
| Shares Outstanding | 65.92M |
| Shares Change (YoY) | +5.21% |
| Shares Change (QoQ) | +5.74% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 46.56% |
| Float | 65.92M |
Valuation Ratios
The trailing PE ratio is 27.57 and the forward PE ratio is 38.50.
| PE Ratio | 27.57 |
| Forward PE | 38.50 |
| PS Ratio | 16.87 |
| Forward PS | 10.98 |
| PB Ratio | 28.20 |
| P/TBV Ratio | 30.15 |
| P/FCF Ratio | 323.69 |
| P/OCF Ratio | 240.78 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 30.10 |
| EV / Sales | 17.24 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 330.86 |
Financial Position
The company has a current ratio of 1.00, with a Debt / Equity ratio of 1.84.
| Current Ratio | 1.00 |
| Quick Ratio | 0.68 |
| Debt / Equity | 1.84 |
| Debt / EBITDA | n/a |
| Debt / FCF | 19.87 |
| Interest Coverage | -0.06 |
Financial Efficiency
Return on equity (ROE) is 332.65% and return on invested capital (ROIC) is -0.90%.
| Return on Equity (ROE) | 332.65% |
| Return on Assets (ROA) | -0.60% |
| Return on Invested Capital (ROIC) | -0.90% |
| Return on Capital Employed (ROCE) | -0.83% |
| Weighted Average Cost of Capital (WACC) | 7.09% |
| Revenue Per Employee | $839,568 |
| Profits Per Employee | $480,917 |
| Employee Count | 1,189 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 0.31 |
Taxes
| Income Tax | -764.67M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.49 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 245.15 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 54.08 |
| Average Volume (20 Days) | 506,550 |
Short Selling Information
The latest short interest is 3.10 million, so 5.61% of the outstanding shares have been sold short.
| Short Interest | 3.10M |
| Short Previous Month | 3.28M |
| Short % of Shares Out | 5.61% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.36 |
Income Statement
In the last 12 months, Ascendis Pharma had revenue of $998.25 million and earned $571.81 million in profits. Earnings per share was $9.26.
| Revenue | 998.25M |
| Gross Profit | 888.81M |
| Operating Income | -17.01M |
| Pretax Income | -192.85M |
| Net Income | 571.81M |
| EBITDA | -3.50M |
| EBIT | -8.38M |
| Earnings Per Share (EPS) | $9.26 |
Balance Sheet
The company has $660.46 million in cash and $1.03 billion in debt, with a net cash position of -$373.39 million or -$5.66 per share.
| Cash & Cash Equivalents | 660.46M |
| Total Debt | 1.03B |
| Net Cash | -373.39M |
| Net Cash Per Share | -$5.66 |
| Equity (Book Value) | 562.63M |
| Book Value Per Share | 9.06 |
| Working Capital | -5.10M |
Cash Flow
In the last 12 months, operating cash flow was $69.93 million and capital expenditures -$17.91 million, giving a free cash flow of $52.02 million.
| Operating Cash Flow | 69.93M |
| Capital Expenditures | -17.91M |
| Depreciation & Amortization | 5.24M |
| Net Borrowing | -31.76M |
| Free Cash Flow | 52.02M |
| FCF Per Share | $0.79 |
Margins
Gross margin is 89.04%, with operating and profit margins of -1.70% and 57.28%.
| Gross Margin | 89.04% |
| Operating Margin | -1.70% |
| Pretax Margin | -19.32% |
| Profit Margin | 57.28% |
| EBITDA Margin | -0.35% |
| EBIT Margin | -0.84% |
| FCF Margin | 5.20% |
Dividends & Yields
Ascendis Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.21% |
| Shareholder Yield | -5.21% |
| Earnings Yield | 3.40% |
| FCF Yield | 0.31% |
Analyst Forecast
The average price target for Ascendis Pharma is $309.43, which is 20.76% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $309.43 |
| Price Target Difference | 20.76% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (3Y) | 50.68% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ascendis Pharma has an Altman Z-Score of -1.05 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.05 |
| Piotroski F-Score | 5 |